Itraconazole-Loaded Poly(Lactic-Co-Glycolic) Acid Nanoparticles for Improved Antifungal Activity

• Jung SH , LimDH, LeeJE, JeongKS, SeongH, ShinBC: Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics.Eur. J. Pharm. Sci.37(3–4), 313–320 (2009).
   PubMed Web of Science ®Google Scholar
• Odds FC , BrownAJP, GowNAR: Antifungal agents: mechanisms of action.Trends Microbiol.11(6), 272–279 (2003).
   PubMed Web of Science ®Google Scholar
• Willems L , Van Der Geest R, De Beule K: Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J. Clin. Pharm. Ther.26(3), 159–169 (2001).
   PubMed Web of Science ®Google Scholar
• Peeters J , NeeskensP, TollenaereJP, RemoorterePV, BrewsterME: Characterization of the interaction of 2-hydroxypropyl-β-cyclodextrin with itraconazole at pH 2, 4, and 7.J. Pharm. Sci.91(6), 1414–1422 (2002).
   PubMed Web of Science ®Google Scholar
• Debeule K : Itraconazole: pharmacology, clinical experience and future development.Int. J. Antimicrob. Agents6(3), 175–181 (1996).
   PubMed Web of Science ®Google Scholar
• Akkar A , MüllerRH: Intravenous itraconazole emulsions produced by solemuls technology.Eur. J. Pharm. Biopharm.56(1), 29–36 (2003).
   PubMed Web of Science ®Google Scholar
• Chen W , GuB, WangH, PanJ, LuW, HouH: Development and evaluation of novel itraconazole-loaded intravenous nanoparticles.Int. J. Pharm.362(1–2), 133–140 (2008).
   PubMedGoogle Scholar
• Yi Y , YoonHJ, KimBOet al.: A mixed polymeric micellar formulation of itraconazole: characteristics, toxicity and pharmacokinetics.J. Control. Release117(1), 59–67 (2007).
   PubMed Web of Science ®Google Scholar
• Panyam J , LabhasetwarV: Biodegradable nanoparticles for drug and gene delivery to cells and tissue.Adv. Drug Deliv. Rev.55(3), 329–347 (2003).
   PubMed Web of Science ®Google Scholar
• Bala I , HariharanS, KumarM: PLGA nanoparticles in drug delivery: the state of the art.Crit. Rev. Ther. Drug Carrier Syst.21(5), 387–422 (2004).
   PubMed Web of Science ®Google Scholar
• Pandey R , AhmadZ, SharmaS, KhullerGK: Nano-encapsulation of azole antifungals: Potential applications to improve oral drug delivery.Int. J. Pharm.301(1–2), 268–276 (2005).
   PubMedGoogle Scholar
• Brannon-Peppas L , BlanchetteJO: Nanoparticle and targeted systems for cancer therapy.Adv. Drug Delivery Rev.56(11), 1649–1659 (2004).
   PubMed Web of Science ®Google Scholar
• Desai MP , LabhasetwarV, WalterE, LevyRJ, Amidon Gl: The mechanism of uptake of biodegradable microparticles in CaCO-2 cells is size dependent. Pharmaceut. Res.14(11), 1568–1573 (1997).
   PubMed Web of Science ®Google Scholar
• Panyam J , Zhou W-Z, Prabha S, Sahoo SK, Labhasetwar V: Rapid endo-lysosomal escape of poly(Dl-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J.16(10), 1217–1226 (2002).
   PubMed Web of Science ®Google Scholar
• Vicari L , MusumeciT, GiannoneIet al.: Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity.BMC Cancer8(1), 212 (2008).
   PubMedGoogle Scholar
• Win KY , FengSS: Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs.Biomaterials26(15), 2713–2722 (2005).
   PubMed Web of Science ®Google Scholar
• Esmaeili F , Hosseini-NasrM, Rad-MalekshahiM, SamadiN, AtyabiF, DinarvandR: Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles.Nanomedicine3(2), 161–167 (2007).
   PubMed Web of Science ®Google Scholar
• Italia J l, Yahya MM, Singh D, Kumar MNVR: Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared with intravenous fungizonea®. Pharm. Res. (Dordrecht)26(6), 1324–1331 (2009).
   PubMed Web of Science ®Google Scholar
• Peng HS , LiuXJ, LvGXet al.: Voriconazole into plga nanoparticles: improving agglomeration and antifungal efficacy.Int. J. Pharm.352(1–2), 29–35 (2008).
   PubMedGoogle Scholar
• Yang W , WiederholdNP, WilliamsRO: Drug delivery strategies for improved azole antifungal action.Expert Opin. Drug Deliv.5(11), 1199–1216 (2008).
   PubMed Web of Science ®Google Scholar
• Kramer MR , MerinG, RudisEet al.: Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (fk 506).Transplant. Proc.29(6), 2657–2659 (1997).
   PubMed Web of Science ®Google Scholar
• Lass-Florl C , NaglM, SpethC, UlmerH, DierichMP, WurznerR: Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.Antimicrob. Agents Chemother.45(1), 124–128 (2001).
   PubMed Web of Science ®Google Scholar
• Maschmeyer G , RuhnkeM: Update on antifungal treatment of invasive Candida and Aspergillus infections.Mycoses47(7), 263–276 (2004).
   PubMed Web of Science ®Google Scholar
• Rajasekaran K , CaryJW, CottyPJ, ClevelandTE: Development of a Gfp-expressing Aspergillus flavus strain to study fungal invasion, colonization, and resistance in cottonseed.Mycopathologia165(2), 89–97 (2008).
   PubMed Web of Science ®Google Scholar
• Wicklow DT , BobellJR, PalmquistDE: Effect of intraspecific competition by Aspergillus flavus on aflatoxin formation in suspended disc culture.Mycol. Res.107(5), 617–623 (2003).
   PubMedGoogle Scholar
• Prabha S , ZhouWZ, PanyamJ, LabhasetwarV: Size-dependency of nanoparticle-mediated gene transfection: studies with fractionated nanoparticlesInt. J. Pharm.244(1–2), 105–115 (2002).
   PubMedGoogle Scholar
• Mccarron PA , DonnellyRF, MaroufW: Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure.J. Microencapsul.23(5), 480–498 (2006).
   PubMed Web of Science ®Google Scholar
• Mittal G , SahanaDK, BhardwajV, Ravi Kumar MNV: Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J. Control. Release119(1), 77–85 (2007).
   PubMed Web of Science ®Google Scholar
• Yoshida Y : Cytochrome p450 of fungi: primary target for azole antifungal agents.Curr. Top. Med. Mycol.2, 388–418 (1988).
   PubMedGoogle Scholar
• Vanden B ossche H, Marichal P, Le Jeune L, Coene MC, Gorrens J, Cools W: Effects of itraconazole on cytochrome p-450-dependent sterol 14 α-demethylation and reduction of 3-ketosteroids in cryptococcus neoformans. Antimicrob. Agents Chemother.37(10), 2101–2105 (1993).
   PubMed Web of Science ®Google Scholar
• Wosten HAB , De Vocht ML: Hydrophobins, the fungal coat unravelled. Biochim. Biophys. Acta1469(2), 79–86 (2000).
   PubMed Web of Science ®Google Scholar
• Wessels JGH : Hydrophobins, unique fungal proteins.Mycologist14(4), 153–159 (2000).
   Google Scholar
• Xu PS , GullottiE, TongLet al.: Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited.Mol. Pharm.6(1), 190–201 (2009).
   PubMedGoogle Scholar
• The Growing Fungus. Neil AR, Gow GMG (Eds). Chapman & Hall, London, UK (1995).
   Google Scholar
• Amaral AC , BoccaAL, RibeiroAMet al.: Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis.J. Antimicrob. Chemother.63(3), 526–533 (2009).
   PubMed Web of Science ®Google Scholar
• Griffin DH : Fungal Physiology (2nd Edition). Wiley-Liss, DE, USA (1994).
   Google Scholar
• Italia JL , BhattDK, BhardwajV, TikooK, KumarMNVR: PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to sandimmune neoral®. J. Control. Release119(2), 197–206 (2007).
   PubMed Web of Science ®Google Scholar
• Lamprecht A , UbrichN, YamamotoHet al.: Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease.J. Pharm. Exp. Ther.299(2), 775–781 (2001).
   PubMed Web of Science ®Google Scholar
• Takeuchi H , YamamotoH, KawashimaY: Mucoadhesive nanoparticulate systems for peptide drug delivery.Adv. Drug Delivery Rev.47(1), 39–54 (2001).
   PubMed Web of Science ®Google Scholar
• Jung T , KammW, BreitenbachA, KaiserlingE, XiaoJX, KisselT: Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?Eur. J. Pharm. Biopharm.50(1), 147–160 (2000).
   PubMed Web of Science ®Google Scholar
• Avgoustakis K , BeletsiA, PanagiZet al.: Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles.Int. J. Pharm.259(1–2), 115–127 (2003).
   PubMedGoogle Scholar
• Panagi Z , BeletsiA, EvangelatosG, LivaniouE, IthakissiosDS, AvgoustakisK: Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles.Int. J. Pharm.221(1–2), 143–152 (2001).
   PubMedGoogle Scholar
• Bailey MM , BerklandCJ: Nanoparticle formulations in pulmonary drug delivery.Med. Res. Rev.29(1), 196–212 (2009).
   PubMed Web of Science ®Google Scholar
• Beck-Broichsitter M , GaussJ, PackhaeuserCBet al.: Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model.Int. J. Pharm.367(1–2), 169–178 (2009).
   PubMedGoogle Scholar
• Sung JC , PulliamBL, EdwardsDA: Nanoparticles for drug delivery to the lungs.Trends Biotechnol.25(12), 563–570 (2007).
   PubMed Web of Science ®Google Scholar

Websites

• Kauffman CA: Fungal infections in immunocompromised hosts: focus on epidemiologic aspects of infection. National Foundation for Infectious Diseases 1(4), (1998) www.nfid.org/publications/fungal_archive/fungal
   Google Scholar
• US FDA: Potato dextrose agar. In: Bacteriological Analytical Manual. US FDA, MD, USA (2008) www.fda.gov/Food/ScienceResearch/LaboratoryMethods/BacteriologicalAnalyticalManualBAM/UCM063519
   Google Scholar